PMID: 9186599Apr 15, 1997Paper

Human lesion studies

Annals of the New York Academy of Sciences
V Fuster

Abstract

We describe recent information on the atherothrombotic processes leading to the acute coronary syndromes (ACS) in humans. Then, we outline the mechanism of action and impact of lipid-lowering therapy in stabilization and secondary prevention of such processes. We start with (1) definitions of atherosclerotic lesions. In the progression of coronary atherosclerosis, eight morphologically different lesions are defined (Type I to VI) in various phases of disease. (2) Then we discuss vulnerable lipid-rich plaques and ACS. The type IV and Va lesions tend to be relatively small in size, but soft or vulnerable to disruption (with subsequent thrombosis) because of high lipid content (cholesterol esters rather than free cholesterol monohydrate crystals). The above process represents a "passive" phenomenon of plaque disruption. In addition to this "passive" phenomenon, an "active," macrophage-dependent, phenomenon of plaque disruption is evolving. (3) We then show the role of thrombosis in ACS. Monocytes/macrophages in lipid-rich plaques may play a detrimental role after plaque disruption, promoting thrombin generation and thrombosis through the tissue factor pathway, which can be prevented by tissue factor pathway inhibitor. Such thrombo...Continue Reading

References

Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Sep 1, 1991·Circulation·D Steinberg
Oct 1, 1991·Journal of the American College of Cardiology·M NobuyoshiK Kimura
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J N WilcoxD Gordon
Mar 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·D M Small
Jul 1, 1988·Journal of the American College of Cardiology·J A AmbroseV Fuster
Oct 16, 1980·The New England Journal of Medicine·M A DeWoodH T Lang
Aug 1, 1995·Circulation·E FalkV Fuster
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·Z S GalisP Libby
Dec 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J F ToussaintH L Kantor
Aug 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R Guyton, K F Klemp
Oct 1, 1993·Journal of the American College of Cardiology·A I MacIsaacE J Topol
Feb 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·D H Blankenhorn, H N Hodis
Feb 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·H M LoreeR T Lee
Sep 15, 1996·Circulation·J D MarmurM B Taubman
Nov 1, 1996·Lancet·V FusterY Nemerson

❮ Previous
Next ❯

Citations

Aug 2, 2002·Journal of Women's Health & Gender-based Medicine·Megan Rist HaymartRoger S Blumenthal
Oct 22, 2004·QJM : Monthly Journal of the Association of Physicians·M L EigenbrodtJ L Mehta
Apr 29, 2006·Journal of Cardiovascular Medicine·Francesco SaiaPatrick W Serruys
Sep 8, 2010·Trends in Cognitive Sciences·Lauren A LeottiKevin N Ochsner
Feb 26, 2011·The Journal of Headache and Pain·Filippo BrighinaBrigida Fierro
Oct 8, 2004·The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology·Edmund T Rolls
Aug 10, 2005·American Heart Journal·Mary McGrae McDermottLuigi Ferrucci
Oct 22, 2005·Revista española de cardiología·Gastón A Rodríguez-GranilloPatrick W Serruys
Jun 17, 1998·American Heart Journal·V Fuster
Oct 9, 2015·Computational and Mathematical Methods in Medicine·Mehdi JahangiriMahmood Reza Sadeghi
Nov 15, 2006·The European Journal of Neuroscience·Daniela NoaínMarcelo Rubinstein
Apr 27, 2010·Journal of Traumatic Stress·Kristen H WalterJohn Gunstad
Dec 21, 2005·Journal of Sleep Research·Katharina BlatterChristian Cajochen
Jan 17, 2004·The European Journal of Neuroscience·Satoshi Tsujimoto, Toshiyuki Sawaguchi
Jan 19, 1999·Vascular Medicine·V FusterJ H Chesebro
Jul 15, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·W J RogersN Reichek
Feb 19, 2008·Neuroreport·Nicola De Pisapia, Todd S Braver
Feb 2, 2008·Child and Adolescent Psychiatry and Mental Health·Judith SinzigGerd Lehmkuhl
Sep 18, 2007·Neuropsychology Review·Marlene Oscar-Berman, Ksenija Marinković
Feb 1, 2008·The Journal of Primary Prevention·Barbara LopezHilda Pantin
Feb 6, 2008·Expert Review of Cardiovascular Therapy·Héctor M García-GarcíaPatrick W Serruys
Jun 20, 2006·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Michael Hoffmann, Frederick Schmitt
May 14, 2009·Neuroreport·Koji JimuraYasushi Miyashita
Oct 24, 2002·Neuroreport·Francisco BarcelóRobert T Knight
Apr 10, 2004·Neuroreport·Daniel Durstewitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.